NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has agreed to work with MD Anderson spinout ApoCell to make its ApoStream liquid biopsy technology available to biotech and pharmaceutical companies.

ApoStream is a platform for the detection, isolation, and capture of circulating tumor cells (or other rare cells), and does not require the use of labels or antibodies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.